These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2201071)

  • 21. HIV or zidovudine myopathy?
    Gherardi R; Chariot P
    Neurology; 1994 Feb; 44(2):361-2; author reply 362-4. PubMed ID: 8309597
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of interleukin-1, GM-CSF, erythropoietin, and lithium on the toxicity associated with 3'-azido-3'-deoxythymidine (AZT) in vitro on hematopoietic progenitors (CFU-GM, CFU-MEG, and BFU-E) using murine retrovirus-infected hematopoietic cells.
    Gallicchio VS; Hughes NK; Hulette BC; Noblitt L
    J Leukoc Biol; 1991 Dec; 50(6):580-6. PubMed ID: 1940611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.
    Manji H; Harrison MJ; Round JM; Jones DA; Connolly S; Fowler CJ; Williams I; Weller IV
    J Neurol; 1993 Sep; 240(8):479-88. PubMed ID: 8263554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on drug interactions with zidovudine.
    Piscitelli SC; Polis MA
    AIDS Patient Care STDS; 1998 Sep; 12(9):687-90. PubMed ID: 15468442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skeletal muscle involvement in HIV-infected patients.
    Gherardi RK
    Neuropathol Appl Neurobiol; 1994 Jun; 20(3):232-7. PubMed ID: 7936072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zidovudine: five years later.
    McLeod GX; Hammer SM
    Ann Intern Med; 1992 Sep; 117(6):487-501. PubMed ID: 1503352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Toxic drug-induced proximal myopathy in CDC C3 HIV-infection].
    Weisser M
    Praxis (Bern 1994); 1997 Oct; 86(43):1708-10. PubMed ID: 9432697
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of combination interleukin-1 and erythropoietin in ameliorating the hematopoietic toxicity associated with the use of zidovudine administered to normal mice.
    Gallicchio VS; Hughes NK; Tse KF; Gaines H
    Life Sci; 1994; 54(20):PL351-61. PubMed ID: 8190019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.
    McKinney RE; Maha MA; Connor EM; Feinberg J; Scott GB; Wulfsohn M; McIntosh K; Borkowsky W; Modlin JF; Weintrub P
    N Engl J Med; 1991 Apr; 324(15):1018-25. PubMed ID: 1672443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV or zidovudine myopathy?
    Dalakas M
    Neurology; 1994 Feb; 44(2):360-1; author reply 362-4. PubMed ID: 8309594
    [No Abstract]   [Full Text] [Related]  

  • 31. [Monitoring of several hematological parameters of the erythroid series in patients with HIV infection treated with zidovudine].
    Manfredi R; Ricchi E; Costigliola P; Borderi M; Guariento A; Silvestri MG; Chiodo F
    Recenti Prog Med; 1992 Jun; 83(6):361-6. PubMed ID: 1496188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions.
    Lane RJ; McLean KA; Moss J; Woodrow DF
    Neuropathol Appl Neurobiol; 1993 Oct; 19(5):406-13. PubMed ID: 8278024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zidovudine-induced lactic acidosis with acute pancreatitis and myopathy: Lethal and rare complications.
    Mahto SK; Gupta PK; Taneja RS; Singh A
    Indian J Pharmacol; 2018; 50(4):212-214. PubMed ID: 30505059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction.
    Mhiri C; Baudrimont M; Bonne G; Geny C; Degoul F; Marsac C; Roullet E; Gherardi R
    Ann Neurol; 1991 Jun; 29(6):606-14. PubMed ID: 1892364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
    Spruance SL; Pavia AT; Mellors JW; Murphy R; Gathe J; Stool E; Jemsek JG; Dellamonica P; Cross A; Dunkle L
    Ann Intern Med; 1997 Mar; 126(5):355-63. PubMed ID: 9054279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Muscular involvement in HIV infection].
    Gherardi R; Chariot P; Authier FJ
    Rev Neurol (Paris); 1995 Nov; 151(11):603-7. PubMed ID: 8745623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS.
    Krown SE; Paredes J; Bundow D; Polsky B; Gold JW; Flomenberg N
    J Clin Oncol; 1992 Aug; 10(8):1344-51. PubMed ID: 1634925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondrial myopathy caused by long-term zidovudine therapy.
    Dalakas MC; Illa I; Pezeshkpour GH; Laukaitis JP; Cohen B; Griffin JL
    N Engl J Med; 1990 Apr; 322(16):1098-105. PubMed ID: 2320079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group.
    McKinney RE; Pizzo PA; Scott GB; Parks WP; Maha MA; Lehrman SN; Riggs M; Eddy J; Lane BA; Eppes SC
    J Pediatr; 1990 Apr; 116(4):640-7. PubMed ID: 2181102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.